Palbociclib (PD-0332991) HCl

Name: Palbociclib (PD-0332991) HCl
Brand: Selleck Chemicals
SKU: S1116
Rating: 5 (241 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1116

241 publications

Palbociclib (PD-0332991) HCl Chemical Structure

CAS No. 827022-32-2

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Selleck's Palbociclib (PD-0332991) HCl has been cited by 241 publications

Nature, 2020, 17

PubMed: 32555459 ( click the link to review the publication )

Nature, 2020, 583(7817):620-624

PubMed: 32669709 ( click the link to review the publication )

Cell, 2020, 16;181(2):424-441.e21.

PubMed: 32234521 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Stem Cell, 2020, 27(1):50-63.e5

PubMed: 32619518 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Cell, 2019, 176(5):1083-1097

PubMed: 30739799 ( click the link to review the publication )

Nat Med, 2019, 25(2):292-300

PubMed: 30664779 ( click the link to review the publication )

Cancer Discov, 2019, 10.1158/2159-8290.CD-18-0830

PubMed: 31594766 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2018, 553(7686):91-95

PubMed: 29160310 ( click the link to review the publication )

Cell, 2018, 174(5):1127-1142

PubMed: 30078706 ( click the link to review the publication )

Cancer Cell, 2018, 9;34(1):56-68.e9

PubMed: 29990501 ( click the link to review the publication )

Cancer Discov, 2017, 7(10):1168-1183

PubMed: 28801307 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

J Clin Invest, 2020, 134132

PubMed: 33016930 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5305

PubMed: 33082317 ( click the link to review the publication )

Nat Commun, 2020, 2;11(1):2760

PubMed: 32488085 ( click the link to review the publication )

Nat Commun, 2020, 11(1):385

PubMed: 31959756 ( click the link to review the publication )

Sci Adv, 2020, 6(34):eaba8968

PubMed: 32937365 ( click the link to review the publication )

EMBO J, 2020, 2;e104036

PubMed: 32484965 ( click the link to review the publication )
EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

Leukemia, 2020, 10.1038/s41375-020-0943-5

PubMed: 32591645 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2706

PubMed: 32086342 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

J Cell Biol, 2020, 1;219(6)

PubMed: 32236513 ( click the link to review the publication )

J Cell Biol, 2020, 2;219(3)

PubMed: 32211891 ( click the link to review the publication )

Cancer Res, 2020, 80(16):3215-3221

PubMed: 32606000 ( click the link to review the publication )

Cancer Res, 2020, 80(18):3841-3854

PubMed: 32690724 ( click the link to review the publication )

Elife, 2020, 7;9:e44571

PubMed: 32255427 ( click the link to review the publication )

Haematologica, 2020, haematol.2020.249177

PubMed: 32855276 ( click the link to review the publication )

Cancers (Basel), 2020, 6;12(4)

PubMed: 32268485 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32197329 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):754

PubMed: 32934219 ( click the link to review the publication )

Cells, 2020, 26;9(4)

PubMed: 32225025 ( click the link to review the publication )

Cancer Discov, 2020, 13;CD-19-1390

PubMed: 32404308 ( click the link to review the publication )

Cancer Discov, 2020, 4;CD-20-0329

PubMed: 32499221 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(10):2221-2232

PubMed: 32747423 ( click the link to review the publication )

Front Oncol, 2020, 10:563249

PubMed: 33072590 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32708306 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32046095 ( click the link to review the publication )

Sci Rep, 2020, 10(1):18489

PubMed: 33116269 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:280

PubMed: 32624705 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:501

PubMed: 33061853 ( click the link to review the publication )
BMC Cancer, 2020, 20(1):941

PubMed: 32998722 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Breast Cancer, 2020, 10.1007/s12282-020-01090-3

PubMed: 32297248 ( click the link to review the publication )

Nat Struct Mol Biol, 2020, 27(1):92-104

PubMed: 31925410 ( click the link to review the publication )

Nature, 2020, 583(7817):620-624

PubMed: 32669709 ( click the link to review the publication )

Breast Cancer Res, 2020, 22(1):89

PubMed: 32795346 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0236298

PubMed: 32701996 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11574

PubMed: 32665693 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01403-y

PubMed: 32712628 ( click the link to review the publication )

J Pathol, 2020, e5493

PubMed: 32558936 ( click the link to review the publication )

Cancer Cell, 2020, 38(1):44-59.e9

PubMed: 32663469 ( click the link to review the publication )

Clin Transl Med, 2020, 10(1):182-198

PubMed: 32508030 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa653

PubMed: 32761127 ( click the link to review the publication )

Gut, 2019, 68(2):207-217

PubMed: 29703791 ( click the link to review the publication )

Nat Microbiol, 2019, 4(12):2260-2272

PubMed: 31548682 ( click the link to review the publication )

Mol Cell, 2019, 76(4):562-573

PubMed: 31543423 ( click the link to review the publication )

Mol Cell, 2019, 73(1):22-35.e6

PubMed: 30527665 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1373

PubMed: 30914635 ( click the link to review the publication )

Nat Commun, 2019, 10(1):557

PubMed: 30718506 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e11031

PubMed: 31512803 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2769

PubMed: 30692100 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

PLoS Biol, 2019, 17(8):e3000203

PubMed: 31430272 ( click the link to review the publication )
PLoS Biol, 2019, 17(4):e3000228

PubMed: 31039152 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2466-2479

PubMed: 30940663 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )

Cell Rep, 2019, 26(10):2667-2680

PubMed: 30840889 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.119.232603

PubMed: 31481582 ( click the link to review the publication )

Oncogene, 2019, 38(20):3886-3902

PubMed: 30692638 ( click the link to review the publication )

Sci Signal, 2019, 12(601):eaay0482

PubMed: 31575731 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)

PubMed: 31100952 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):271

PubMed: 30894510 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):376

PubMed: 31092814 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cells, 2019, 8(10)

PubMed: 31590445 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(2):300-306

PubMed: 30595531 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):771-779

PubMed: 30837298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0162

PubMed: 31395685 ( click the link to review the publication )

Mol Oncol, 2019, 13(8):1778-1794

PubMed: 31180176 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(1):465-489

PubMed: 29721855 ( click the link to review the publication )

Oncogenesis, 2019, 8(7):38

PubMed: 31209198 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 163:133-141

PubMed: 30772267 ( click the link to review the publication )

J Transl Med, 2019, 17(1):245

PubMed: 31358010 ( click the link to review the publication )
Sci Rep, 2019, 9(1):13405

PubMed: 31527634 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13696

PubMed: 31548560 ( click the link to review the publication )

Mol Pharmacol, 2019, 96(4):419-429

PubMed: 31467029 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29249

PubMed: 31264276 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1685289

PubMed: 31747859 ( click the link to review the publication )

Exp Cell Res, 2019, 10.1016/j.yexcr.2019.111782

PubMed: 31857114 ( click the link to review the publication )

Am J Transl Res, 2019, 11(6):3481-3489

PubMed: 31312360 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

PLoS ONE, 2019,

PubMed: 31891587 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(4):967-973

PubMed: 31005255 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Oncol Lett, 2019, 17(1):1153-1159

PubMed: 30655877 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:22

PubMed: 31372497 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(8):3921-3936

PubMed: 30805632 ( click the link to review the publication )

NPJ Precis Oncol, 2019, 03:18

PubMed: 31341951 ( click the link to review the publication )

Haematologica, 2019, 104(2):347-359

PubMed: 30262555 ( click the link to review the publication )

Oncotarget, 2019, 10(47):4907-4918

PubMed: 31448056 ( click the link to review the publication )

Eur J Med Chem, 2019, 165:115-132

PubMed: 30665142 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 31399419 ( click the link to review the publication )

Gut, 2018, 10.1136/gutjnl-2017-314544

PubMed: 29884612 ( click the link to review the publication )
Mol Cell, 2018, 71(2):332-342

PubMed: 30017584 ( click the link to review the publication )

Mol Cell, 2018, 71(4):592-605

PubMed: 30057199 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(12):6188-6205

PubMed: 29873780 ( click the link to review the publication )

Autophagy, 2018, 14(4):637-653

PubMed: 29368982 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3994-4005

PubMed: 29716919 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-3094

PubMed: 30538112 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4360-4369

PubMed: 29844123 ( click the link to review the publication )

Cell Rep, 2018, 24(5):1105-1112.e5

PubMed: 30067968 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Oncogene, 2018, 37(37):5066-5078

PubMed: 29789718 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):446

PubMed: 29670090 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):897-907

PubMed: 29483214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582

PubMed: 29452249 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cell Signal, 2018, 44:1-9

PubMed: 29284139 ( click the link to review the publication )

J Orthop Res, 2018, 36(6):1581-1589

PubMed: 29194728 ( click the link to review the publication )

Cell Cycle, 2018, 17(11):1329-1344

PubMed: 30037299 ( click the link to review the publication )

Cell Cycle, 2018, 17(14):1784-1796

PubMed: 29995568 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0206368

PubMed: 30383785 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):424-430

PubMed: 29477843 ( click the link to review the publication )
Int J Radiat Oncol Biol Phys, 2018, 102(5):1569-1576

PubMed: 30056081 ( click the link to review the publication )

Oncotarget, 2018, 9(77):34567-34581

PubMed: 30349650 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2018, 21(5):375-382

PubMed: 29764587 ( click the link to review the publication )

Oncotarget, 2018, 9(102):37753-37765

PubMed: 30701029 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell, 2018, 10.1016/j.cell.2018.11.011

PubMed: 30580964 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1061-1070

PubMed: 28759028 ( click the link to review the publication )

Mol Cell, 2017, 68(6):1134-1146

PubMed: 29225033 ( click the link to review the publication )

Nat Commun, 2017, 8(1):607

PubMed: 28928360 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1193

PubMed: 29084956 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1995

PubMed: 29222471 ( click the link to review the publication )

Nat Commun, 2017, 8(1):241

PubMed: 28808226 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(10):1415-1433

PubMed: 28778953 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6958-6968

PubMed: 28814434 ( click the link to review the publication )

Dev Cell, 2017, 43(4):449-462

PubMed: 29103955 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.26957

PubMed: 29889021 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):123

PubMed: 28629371 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(15):2427-2443

PubMed: 28444744 ( click the link to review the publication )

J Mol Cell Biol, 2017, 1;9(2):154-165

PubMed: 27927748 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1942-1953

PubMed: 28566433 ( click the link to review the publication )

Cell Oncol (Dordr), 2017, 40(3):209-218

PubMed: 28243976 ( click the link to review the publication )

Oncogenesis, 2017,

PubMed: 28504693 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )
PLoS One, 2017, 12(8):e0181601

PubMed: 28806746 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(3):676-688

PubMed: 27338091 ( click the link to review the publication )

Protein Sci, 2017, 26(4):870-879

PubMed: 28168755 ( click the link to review the publication )

Oncotarget, 2017, 8(48):83432-83445

PubMed: 29137354 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(56):95116-95134

PubMed: 29221116 ( click the link to review the publication )

Oncotarget, 2017, 8(49):84743-84760

PubMed: 29156680 ( click the link to review the publication )

Oncotarget, 2017, 8(34):55848-55862

PubMed: 28915557 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(4):489-501

PubMed: 28965767 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47239-47249

PubMed: 28525384 ( click the link to review the publication )

Oncotarget, 2017, 8(33):55319-55331

PubMed: 28903422 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:11581

PubMed: 27181366 ( click the link to review the publication )

Nat Commun, 2016, 7:12748

PubMed: 27599659 ( click the link to review the publication )

Nat Commun, 2016, 7:11302

PubMed: 27066737 ( click the link to review the publication )

Nat Commun, 2016, 7:11987

PubMed: 27329820 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(1):122-33

PubMed: 26728409 ( click the link to review the publication )

Cell Mol Life Sci, 2016, 73(4):883-900

PubMed: 26346493 ( click the link to review the publication )

PLoS Pathog, 2016, 12(8):e1005829

PubMed: 27541004 ( click the link to review the publication )

Cell Death Dis, 2016, 7(10):e2419

PubMed: 27735950 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2486-2497

PubMed: 27507850 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(10):3203-3219

PubMed: 27486199 ( click the link to review the publication )
Aging (Albany NY), 2016, 8(12):3535-3551

PubMed: 28077803 ( click the link to review the publication )

J Cancer, 2016, 7(8):947-56

PubMed: 27313785 ( click the link to review the publication )

J Immunol, 2016, 197(7):2673-85

PubMed: 27566829 ( click the link to review the publication )

Sci Rep, 2016, 6:20376

PubMed: 26847534 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2016, 310(7):C520-41

PubMed: 26718628 ( click the link to review the publication )

Oncotarget, 2016, 7(26):39595-39608

PubMed: 27167191 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51163-51173

PubMed: 27323399 ( click the link to review the publication )

Oncotarget, 2016, 7(43):69111-69123

PubMed: 27564114 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Blood, 2015, 24;126(13):1565-74

PubMed: 26254443 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

J Cell Biol, 2015, 210(7):1257-68

PubMed: 26416968 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:76

PubMed: 26225123 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(9):1506-22

PubMed: 25733683 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0140243

PubMed: 26460486 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

J Exp Med, 2015, 212(6):953-70

PubMed: 26008897 ( click the link to review the publication )

Data Brief, 2015, 5:429-33

PubMed: 26958605 ( click the link to review the publication )

Oncotarget, 2015, 6(29):28057-70

PubMed: 26356814 ( click the link to review the publication )

Blood, 2014, 3;124(1):13-23

PubMed: 24764564 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):662-74

PubMed: 24362465 ( click the link to review the publication )

AIDS, 2014, 28(15):2213-22

PubMed: 25036183 ( click the link to review the publication )
J Immunol, 2014, 193(4):1988-97

PubMed: 25015816 ( click the link to review the publication )

FEBS J, 2014, 281(18):4179-94

PubMed: 24823279 ( click the link to review the publication )

BMC Cancer, 2014, 14:32

PubMed: 24444383 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Oncotarget, 2014,

PubMed: 25277205 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Universidade de Lisboa, 2014, Matias

PubMed: ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Cell Death Differ, 2013, 20(9):1241-9

PubMed: 23852369 ( click the link to review the publication )

Int J Cancer, 2013, 133(10):2341-50

PubMed: 23640782 ( click the link to review the publication )

PLoS Genet, 2013, 9(5):e1003546

PubMed: 23737759 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2722-34

PubMed: 24107447 ( click the link to review the publication )

J Virol, 2013, 87(8):4623-41

PubMed: 23408614 ( click the link to review the publication )

Pharmacogenomics J, 2013, 13(1):94-104

PubMed: 22083351 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cell Cycle, 2013, 12(15):2384-94

PubMed: 23839043 ( click the link to review the publication )

PLoS One, 2013, 8(11):e78641

PubMed: 24265703 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4612-20

PubMed: 22761470 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2012, 26(2):236-46

PubMed: 23279822 ( click the link to review the publication )

Am J Cancer Res, 2012, 2(6):726-35

PubMed: 23226618 ( click the link to review the publication )

Cell Cycle, 2012, 11(19):3599-610

PubMed: 22935696 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51847

PubMed: 23300567 ( click the link to review the publication )

georgetown university, 2012, georgetown university

PubMed: ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(20):8414-9

PubMed: 21536883 ( click the link to review the publication )
Clin Cancer Res, 2011, 1;17(13):4513-22

PubMed: 21593195 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Features

Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Targets

CDK4/CyclinD3 ^[1] (Cell-free assay)	CDK4/CyclinD1 ^[1] (Cell-free assay)	CDK6/CyclinD2 ^[1] (Cell-free assay)
9 nM	11 nM	15 nM

In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser⁷⁸⁰. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. ^[1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. ^[2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. ^[3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MOLM13	M2\kZWtqdmG\|ZTDBd5NigQ>?		NGfZdHczPCCq		NFjQemtKdmirYnn0bY9vKG:oIFPET\|Qh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFAzKM7:TR?=	MoH1NlQ3PDFzMEO=
COLO205	MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1fKclczKGh?		NUTnWY9CSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO\|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkCzOkDPxE1?	MV6yOFY1OTFyMx?=
U937	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1jhOFczKGh?		M2ewdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5zNDFOwG0>	Mn7PNlQ3PDFzMEO=
MOLM13	NUPKcHlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{\3NFczKGh?		MYPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xN{Bk\WyuczDoZZJjd3KrbnegSmxVOyCLVFSgcZV1[W62IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX\|NJZXSqeX3p[Ilv\SCrboTvJGRPSSC5aYToJGlEPTBib3[gNE4xQTZizszN	NGG1bnEzPDZ2MUGwNy=>
MOLM13	NXr3VVlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEK4eHI4OiCq		MmThRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDzc5Ji\mWwaXKtdoV{cXO2YX70JIh2dWGwIF3PUG0yOyClZXzsd{Bie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>?	NWL2VVlEOjR4NEGxNFM>
MDA-MB-435	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlzLNlQhcA>?		MmrUTWM2OD1yLkG2JO69VQ>?	Mlq0NVU5ODF6M{G=
K562	MWnDfZRwfG:6aXOgRZN{[Xl?		MUO5OkBp	MVHEUXNQ	NVn4e3o4UUN3ME2yJO69VQ>?	MYCyOFQyPzV4Nh?=
DU145	MmP4R5l1d3SxeHnjJGF{e2G7		MofUPVYhcA>?	MlTISG1UVw>?	M4C0XWlEPTB;Nz61JO69VQ>?	NWDPTHlrOjR2MUe1OlY>
MDA-MB-231	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfOVIUyKM7:TR?=	M3zxSFI1KGh?	MXPEUXNQ	MYTD[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS\|EheGijc3W=	NV;PWXh{OjR2MUe1OlY>
MCF7	NX;POVZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVr1WplWOSEQvF2=	Ml;oNlQhcA>?	M{fuSWROW09?	NETES\|NE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U>	M3HZTVI1PDF5NU[2
MCF7	NWHhWXFCU2mwYYPlJGF{e2G7	M13hSlUh\|ryP	NWSzTnBKOjRiaB?=	M3TFNWROW09?	NH74XlJKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGNFUzRxY4njcIlvTDFiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iC{ZYTpco9jdGG\|dH;tZUBxcG:\|cHjvdplt[XSrb36gZZQhW2W{N{iw	NVLQOoNVOjR2MUe1OlY>
MDA-MB-231	NHfxTJFMcW6jc3WgRZN{[Xl?	NUTNcYNyPSEQvF2=	NHfXVIQzPCCq	MYPEUXNQ	MW\Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFPET\|Qw[3mlbHnuSFEh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBz\XSrbn;icIF{fG:vYTDwbI9{eGixconsZZRqd25iYYSgV4VzPzhy	NFGxVIszPDRzN{W2Oi=>
MDA-MB-231	MkHkSpVv[3Srb36gRZN{[Xl?	M3jDc\|EuOTBizszN	MnzJNlQhcA>?	MXzEUXNQ	NIrJ[4lld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W\|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W=	NFy3bVQzPDRzN{W2Oi=>
MCF7	NITnN3lHfW6ldHnvckBCe3OjeR?=	NHz6dlIyNTFyIN88US=>	M3vQRlI1KGh?	MmGwSG1UVw>?	NIHTRVVld2W\|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W\|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W=	M{W5OFI1PDF5NU[2
MDA-MB-231	M{H3e2Z2dmO2aX;uJGF{e2G7	M4X1U\|AvPS1zIN88US=>	MmPLOFghcA>?	MVnEUXNQ	MVHoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=>	Mn[2NlQ1OTd3Nk[=
MCF7	MnK5SpVv[3Srb36gRZN{[Xl?	MXiwMlUuOSEQvF2=	MXO0PEBp	M{K3OmROW09?	MVroZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=>	M2WxO\|I1PDF5NU[2
697	NH;WboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnoUo1EUUN3ME2xOFgvOzhibl2=	M4KxWHNCVkeHUh?=
P12-ICHIKAWA	NELuUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PnUGlEPTB;OU[uNFQhdk1?	MVjTRW5ITVJ?
NB69	NFLUd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\PWZhYUUN3ME2xOlEvQCCwTR?=	M{XabXNCVkeHUh?=
EoL-1	NFP4eolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHRTGVKSzVyPUG4O{4zPiCwTR?=	NGG4TIJUSU6JRWK=
BHT-101	NUTHTZpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PUeGlEPTB;MUm4MlI2KG6P	MlH4V2FPT0WU
SK-NEP-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojVTWM2OD1{MkCuNFIhdk1?	NIPVT3FUSU6JRWK=
MHH-NB-11	NIfnOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTJ{MD6xPUBvVQ>?	NX6xXYZLW0GQR1XS
AsPC-1	NF;YS2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzmWXJDUUN3ME2yOVIvPTNibl2=	MXfTRW5ITVJ?
ES1	NUXpOXo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLxTWM2OD1{NU[uNlUhdk1?	NE\EWIRUSU6JRWK=
LAMA-84	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\neGlEPTB;MkW4MlE6KG6P	M17tN3NCVkeHUh?=
MOLT-16	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTJ3OD60PUBvVQ>?	MYrTRW5ITVJ?
ES7	NYi4OHBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\2VZZKUUN3ME2yO\|MvODlibl2=	NGPkV29USU6JRWK=
KY821	MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTNzND6xJI5O	MXrTRW5ITVJ?
RT-112	NWjZ[HR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFLrSJNKSzVyPUOyNU4xPSCwTR?=	M{DocHNCVkeHUh?=
HL-60	MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTN2MD62OkBvVQ>?	MnrlV2FPT0WU
MOLT-4	MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTN2NT6xN{BvVQ>?	M3nkRnNCVkeHUh?=
KARPAS-45	NXHDVJRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfvXXY3UUN3ME2zO\|YvOTZibl2=	MVnTRW5ITVJ?
SK-N-AS	NXHuRlJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTN6Nz64N{BvVQ>?	MWjTRW5ITVJ?
CTB-1	M1r0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPPXYxrUUN3ME20NFUvODJibl2=	M1rYfnNCVkeHUh?=
NKM-1	NUPBVWdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjrXWpNUUN3ME20NVEvQDlibl2=	MnrsV2FPT0WU
HTC-C3	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTqe4dwUUN3ME20N\|IvQTVibl2=	MWHTRW5ITVJ?
BE-13	NHjHc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7LTWM2OD12NESuNlchdk1?	NF6yfYpUSU6JRWK=
KOSC-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn35TWM2OD12Nk[uPUBvVQ>?	MWHTRW5ITVJ?
NB14	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnCfWtVUUN3ME20PFMvPThibl2=	NH7V[GZUSU6JRWK=
CAL-27	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFexZoFKSzVyPUS5OE42QSCwTR?=	M4TsUXNCVkeHUh?=
H9	NFfO[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1qzdGlEPTB;NEm1MlQ{KG6P	NHTy[GJUSU6JRWK=
RS4-11	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFewcWxKSzVyPUWwOE44OyCwTR?=	NGjnN3FUSU6JRWK=
PA-1	NXPOPXBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml[zTWM2OD13MEmuPFYhdk1?	MWrTRW5ITVJ?
MV-4-11	NITsboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYTJR\|UxRTVzMz64OUBvVQ>?	NX;pW\|VsW0GQR1XS
OS-RC-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF60TndKSzVyPUWyNU43OiCwTR?=	Mo\UV2FPT0WU
RPMI-8226	MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXaTWM2OD13Mk[uPFYhdk1?	MX7TRW5ITVJ?
HGC-27	NFixXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTV4ND65PUBvVQ>?	M2HRPXNCVkeHUh?=
CHP-212	MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG[1ZlZKSzVyPUW5N{42QSCwTR?=	NFTYXopUSU6JRWK=
NB10	M3rZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTV7OT6xPEBvVQ>?	NVvZfXA3W0GQR1XS
HH	M{HSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLseWJKSzVyPUW5PU41OyCwTR?=	Ml3UV2FPT0WU
EW-16	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3LTWM2OD14MEOuOVIhdk1?	M1nQXHNCVkeHUh?=
ES8	NHnWdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3j0VmlEPTB;NkC1MlIyKG6P	MVXTRW5ITVJ?
HAL-01	NV\WOoVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrKUJdKSzVyPU[wOU43PyCwTR?=	NYTzVVBSW0GQR1XS
A204	M{HPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MorGTWM2OD14M{OuPVEhdk1?	MlGyV2FPT0WU
MHH-PREB-1	M3fsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M360WWlEPTB;NkO2Mlk6KG6P	NFzUXFRUSU6JRWK=
EM-2	MmTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TUb2lEPTB;NkWwMlY1KG6P	NH;mS\|hUSU6JRWK=
BV-173	M4ryRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPDS\|VKSzVyPU[1Nk41QCCwTR?=	MUTTRW5ITVJ?
ONS-76	M4nQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmewTWM2OD14N{euPFIhdk1?	MUnTRW5ITVJ?
KM-H2	MlzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1SyOGlEPTB;Nkm1MlU1KG6P	M3zQc3NCVkeHUh?=
D-263MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLQTWM2OD15MUeuNVIhdk1?	MX\TRW5ITVJ?
ES3	NFrKdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTnWpRsUUN3ME23NlgvQTNibl2=	NF[weYlUSU6JRWK=
VA-ES-BJ	NGDkbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PyZ2lEPTB;N{OyMlI4KG6P	NG\6UlJUSU6JRWK=
NBsusSR	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\leIR1UUN3ME23OFIvQTlibl2=	M3vqbHNCVkeHUh?=
NCI-H520	MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rrZWlEPTB;N{S2MlUzKG6P	MXnTRW5ITVJ?
ES5	NGHs[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHjUZZKSzVyPUe1Nk45KG6P	NHf5cXhUSU6JRWK=
T-24	NH[zNWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml:yTWM2OD15N{iuO\|Ehdk1?	MXLTRW5ITVJ?
SW962	NYrD[2x{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnySGl[UUN3ME24NFgvPjNibl2=	MU\TRW5ITVJ?
EW-3	Mn[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRThyOD63OkBvVQ>?	NGjPV4tUSU6JRWK=
RXF393	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnT0TWM2OD16MUKuO\|khdk1?	NIjGR3BUSU6JRWK=
U251	MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnxRZFKSzVyPUixN{45QCCwTR?=	NVr3N4NNW0GQR1XS
CAMA-1	NHO1cVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLUW5hWUUN3ME24N\|MvQTRibl2=	MWLTRW5ITVJ?
JVM-3	MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTh3MT63PEBvVQ>?	NGG3Om5USU6JRWK=
COLO-800	NFXPUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzKTWM2OD16OUeuO\|ghdk1?	NEj5VWZUSU6JRWK=
OVCAR-5	M1zUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml2zTWM2OD17MECuNUBvVQ>?	MVvTRW5ITVJ?
LB1047-RCC	M3LiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrLTWtKUUN3ME25NlcvPTZibl2=	NYX6SHpmW0GQR1XS
SW954	M2\pbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPsZ21KSzVyPUmyPU41OSCwTR?=	NV76WHBxW0GQR1XS
J-RT3-T3-5	M4rxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLwUHZvUUN3ME25N\|YvODZibl2=	NEHodXlUSU6JRWK=
Mewo	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DDcWlEPTB;OUO2MlYhdk1?	MlrZV2FPT0WU
NCI-H1770	NHnYNGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnWyTWM2OD17NECuOVUhdk1?	Ml7BV2FPT0WU
HO-1-N-1	Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnpdIdKSzVyPUm2Nk45OSCwTR?=	MoWwV2FPT0WU
HSC-3	NUe2dpdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDsfJVCUUN3ME25OlYvPDhibl2=	M3vY[3NCVkeHUh?=
TYK-nu	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTl7OD6yOUBvVQ>?	M1;jSHNCVkeHUh?=
KYSE-150	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFfOU2JKSzVyPUGuNFAxPzZizszN	M{nCd3NCVkeHUh?=
SN12C	NVnxem1IT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7SclZKSzVyPUGuNFA5PzVizszN	M1exbXNCVkeHUh?=
MOLT-13	MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3z0dmlEPTB;MT6wNVQzOSEQvF2=	MYjTRW5ITVJ?
TE-11	M3jxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXaTWM2OD1zLkC0PFEzKM7:TR?=	NGfuO4ZUSU6JRWK=
DB	NY\OVoJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzVUpNKSzVyPUGuNFczPzNizszN	NGDhe5FUSU6JRWK=
CAL-39	M3S4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvYTWM2OD1zLkC3OVIzKM7:TR?=	MW\TRW5ITVJ?
A3-KAW	NFXTNmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrnTWM2OD1zLkC4OFA5KM7:TR?=	MVPTRW5ITVJ?
CHP-134	M4O3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vLdGlEPTB;MT6xNVgxPyEQvF2=	MYTTRW5ITVJ?
TGW	M1ztWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTFwMUKzPVUh\|ryP	NFfYfHhUSU6JRWK=
QIMR-WIL	NUDHR3d4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXv2NVgyUUN3ME2xMlE{OTN2IN88US=>	M1\HUHNCVkeHUh?=
NCI-SNU-1	M2fkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnOTWM2OD1zLkG2N\|U1KM7:TR?=	NVX0cXpOW0GQR1XS
CGTH-W-1	M3Lpe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYjpepB2UUN3ME2xMlE4OTh4IN88US=>	MnnsV2FPT0WU
MHH-ES-1	NYTuRlFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTFwMUe5PFYh\|ryP	NH:5NmpUSU6JRWK=
LB2241-RCC	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTFwMUi2NkDPxE1?	MljNV2FPT0WU
ML-2	NE\DU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjiOnNxUUN3ME2xMlIxPzN2IN88US=>	MonXV2FPT0WU
COR-L23	MmnUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{[xRWlEPTB;MT6yNlk{OyEQvF2=	NGO0NoNUSU6JRWK=
BFTC-905	MlvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnNTWM2OD1zLkK0NlY4KM7:TR?=	M2f5PHNCVkeHUh?=
Hs-578-T	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTFwMkW4NVch\|ryP	NWq2NZV2W0GQR1XS
KG-1	NYDORmlpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjtNWMzUUN3ME2xMlI3Pjh4IN88US=>	NHTibohUSU6JRWK=
HEL	M2G2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYHJR\|UxRTFwMkmzN\|gh\|ryP	MlHXV2FPT0WU
A549	M2PLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\hTmlEPTB;MT6yPVM6QSEQvF2=	NVTJUGxGW0GQR1XS
COLO-741	NVe0R2hOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLFPGxKSzVyPUGuN\|IxQDlizszN	NX3TO2U6W0GQR1XS
PC-3	MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXryTYg4UUN3ME2xMlM2OjJzIN88US=>	MV\TRW5ITVJ?
HOS	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmD3TWM2OD1zLkO1Nlk3KM7:TR?=	Mm\FV2FPT0WU
HT-1080	NUDL[ndvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE[2e5lKSzVyPUGuN\|c2OTlizszN	NIHFSpBUSU6JRWK=
TE-8	NIDwN21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvCTWM2OD1zLkSxO\|c1KM7:TR?=	MonkV2FPT0WU
BHY	M2nEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLVTWM2OD1zLkS2PVI{KM7:TR?=	MmTkV2FPT0WU
BB65-RCC	NUC2N2tmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2X6R2lEPTB;MT61NFUzQCEQvF2=	NVnReFlzW0GQR1XS
HN	MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPQTWM2OD1zLkW0NFcyKM7:TR?=	M1T6NnNCVkeHUh?=
NCI-H441	NEi4SGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDGcWt1UUN3ME2xMlU1QTB5IN88US=>	NXy1UI9KW0GQR1XS
RPMI-8866	NULBXGpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHGxTVhKSzVyPUGuOVg2ODdizszN	MnLJV2FPT0WU
CAL-62	M4XhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7LOINKSzVyPUGuOlA5PjJizszN	MmXuV2FPT0WU
MG-63	M37aeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnncoExUUN3ME2xMlYyQDF\|IN88US=>	MmD3V2FPT0WU
SK-LU-1	Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mle4TWM2OD1zLk[yNVUzKM7:TR?=	MlHBV2FPT0WU
BCPAP	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTFwNk[0OVch\|ryP	NYnnXmZ7W0GQR1XS
22RV1	NViwUpZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFmxOYhKSzVyPUGuOlc5PDNizszN	MmnaV2FPT0WU
T47D	M4C4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfM[IR{UUN3ME2xMlY5ODZzIN88US=>	MlqyV2FPT0WU
MSTO-211H	NIXXZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTFwNkm2NFMh\|ryP	NIL1SIlUSU6JRWK=
DEL	NFPSVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXrBZlltUUN3ME2xMlcxOjd\|IN88US=>	Ml7uV2FPT0WU
H4	NVLnZYFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NES5[npKSzVyPUGuO\|MzOTJizszN	MWXTRW5ITVJ?
CAL-51	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\VbpJLUUN3ME2xMlc1QDV3IN88US=>	MU\TRW5ITVJ?
ABC-1	NVfRSJhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjnc4V[UUN3ME2xMlc5PTh{IN88US=>	M37SVnNCVkeHUh?=
MZ2-MEL	NI\Hd\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIe4XJZKSzVyPUGuO\|k2PDJizszN	MUDTRW5ITVJ?
YKG-1	NHjU[I5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTFwOEGwOlEh\|ryP	Ml64V2FPT0WU
KM12	NGi3OGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTFwOEG2NFIh\|ryP	NYLQZ\|Z{W0GQR1XS
L-363	NYnZXlVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRTFwOEe0NVIh\|ryP	MXXTRW5ITVJ?
KU812	NWLJ[HdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWP2ZnJTUUN3ME2xMlg6Ojh{IN88US=>	MXvTRW5ITVJ?
LOXIMVI	NWDocI9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfWNZVvUUN3ME2xMlkyOjJ6IN88US=>	NWfid5F2W0GQR1XS
G-401	M{jCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEX2U5NKSzVyPUGuPVI1OjhizszN	M2TVZ3NCVkeHUh?=
SW780	Mk\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTld\|hKSzVyPUGuPVYzPDZizszN	Mm\VV2FPT0WU
SW872	M3jFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3ETWM2OD1zLkm4N\|Mh\|ryP	MXrTRW5ITVJ?
NB7	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIL6S\|NKSzVyPUGuPVk{OjNizszN	NYPpfVZzW0GQR1XS
T98G	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXj[ZBKSzVyPUKuNFA3PjZizszN	MYDTRW5ITVJ?
SW1710	Ml;6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3HEWGlEPTB;Mj6wOlk1PSEQvF2=	NUnsfItpW0GQR1XS
NCI-H1573	NVjuSIpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\OV2lEPTB;Mj6wO\|I6QCEQvF2=	MnnFV2FPT0WU
KE-37	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFj5VYdKSzVyPUKuNFg6PTFizszN	MlLzV2FPT0WU
786-0	M1PnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXvNYhnUUN3ME2yMlE2PDN7IN88US=>	MkD2V2FPT0WU
SAS	Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnv2TWM2OD1{LkKwN\|c1KM7:TR?=	MVzTRW5ITVJ?
CAL-54	M1fsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\uTWM2OD1{LkKwOFE{KM7:TR?=	M17hVHNCVkeHUh?=
SF268	NHToTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTJwMkOxNlIh\|ryP	MnXIV2FPT0WU
SW620	MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{PBU2lEPTB;Mj6yOlE3QSEQvF2=	NH3BOWNUSU6JRWK=
MN-60	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTJwM{GwOkDPxE1?	NW\6eppLW0GQR1XS
EFO-27	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LVTmlEPTB;Mj6zNlA2QCEQvF2=	MoT5V2FPT0WU
NCI-H747	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\sTWM2OD1{LkOyNVk6KM7:TR?=	NWDPUI1MW0GQR1XS
HCC2218	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTJwM{WzO\|Qh\|ryP	M3PQTXNCVkeHUh?=
MIA-PaCa-2	MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjr[oxKSzVyPUKuN\|Y1OzdizszN	NWnpc2tXW0GQR1XS
SJSA-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTJwM{e3PVYh\|ryP	M1;N[HNCVkeHUh?=
RKO	NXPGbW51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrFTWM2OD1{LkO4OFk3KM7:TR?=	NYH1UpZtW0GQR1XS
NB6	Mn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M374T2lEPTB;Mj60NFM4PCEQvF2=	MkjuV2FPT0WU
ES4	NWLacIw3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTQTWM2OD1{LkS1OFIzKM7:TR?=	MmD0V2FPT0WU
EGI-1	MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnSN29[UUN3ME2yMlQ3QDh\|IN88US=>	NEL1[4tUSU6JRWK=
CTV-1	M1Gzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3wTWM2OD1{LkWyO\|c{KM7:TR?=	MorvV2FPT0WU
NCI-H1355	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33YPWlEPTB;Mj61OVk2OSEQvF2=	NF\CUmdUSU6JRWK=
GT3TKB	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTJwNUmxPVkh\|ryP	Ml2yV2FPT0WU
SK-HEP-1	M1rIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPZdIxKSzVyPUKuOVkzPjZizszN	NXezZY52W0GQR1XS
GAMG	NHjhe25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\nd2lEPTB;Mj61PVM6PCEQvF2=	MoO1V2FPT0WU
SK-MES-1	NHX1Um9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvzdnBJUUN3ME2yMlYyQDB\|IN88US=>	NGqyNGxUSU6JRWK=
RO82-W-1	NVvnOnhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\xVGlEPTB;Mj62NlA2PyEQvF2=	MVTTRW5ITVJ?
ECC10	MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrRXnBKSzVyPUKuO\|AzODZizszN	Mn\mV2FPT0WU
MCF7	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mof1TWM2OD1{LkexOFY1KM7:TR?=	NF;acmZUSU6JRWK=
D-283MED	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HOR2lEPTB;Mj63NlQ{KM7:TR?=	NGG2cJRUSU6JRWK=
RPMI-7951	NH3sWFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmi4TWM2OD1{Lke1Olk1KM7:TR?=	NVXjV3NIW0GQR1XS
Ramos-2G6-4C10	NUWzNGVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTJwN{ewPVkh\|ryP	NE\ESm5USU6JRWK=
KGN	MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHf1cmxKSzVyPUKuPFE5QDRizszN	MljxV2FPT0WU
NUGC-3	MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rpdGlEPTB;Mj64NlUxPSEQvF2=	MnfXV2FPT0WU
NCI-H292	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELPWXlKSzVyPUKuPFUxPTNizszN	M1O3NnNCVkeHUh?=
Becker	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HKUGlEPTB;Mj65OVg{OiEQvF2=	M{C0TnNCVkeHUh?=
NCI-H1299	MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljYTWM2OD1\|LkC1NlY{KM7:TR?=	NHfscYlUSU6JRWK=
ETK-1	NHXMSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TmUmlEPTB;Mz6wOVQ{KM7:TR?=	MXnTRW5ITVJ?
TK10	NEizS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTNwMkCxOlUh\|ryP	MVzTRW5ITVJ?
VMRC-RCZ	M4W5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFq3XVFKSzVyPUOuN\|Y1QDhizszN	MYfTRW5ITVJ?
YH-13	MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXTdVN3UUN3ME2zMlQ1ODd7IN88US=>	MnXFV2FPT0WU
DU-145	MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTNwNE[yOlkh\|ryP	MlLSV2FPT0WU
SW1088	NHrQWphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTNwNEe0O{DPxE1?	NY\3ZXNzW0GQR1XS
HOP-92	M{DRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnhOFV[UUN3ME2zMlUxOzR{IN88US=>	MoLxV2FPT0WU
KP-N-YS	NHvROplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4m0RWlEPTB;Mz62NlE{QSEQvF2=	Mn2yV2FPT0WU
NCI-H460	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\GVmJ1UUN3ME2zMlY3PzNizszN	M{PESHNCVkeHUh?=
U-2-OS	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWXFXo9MUUN3ME2zMlczPTN3IN88US=>	MnnCV2FPT0WU
A101D	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4S2NmlEPTB;Mz63Olk{PiEQvF2=	M{\0NHNCVkeHUh?=
MDA-MB-231	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTNwOEG5OVEh\|ryP	MlzFV2FPT0WU
IST-MES1	MmnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmrSTWM2OD1\|LkizNkDPxE1?	NF3kd4ZUSU6JRWK=
COR-L105	M13xU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTRwMEG4JO69VQ>?	MoLkV2FPT0WU
NCI-H1437	M3jCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUL5NndrUUN3ME20MlAzOzB{IN88US=>	MVTTRW5ITVJ?
CAL-85-1	NGG0XnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTF[ml3UUN3ME20MlAzPDZzIN88US=>	Mn\WV2FPT0WU
MZ1-PC	NGjIPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzlTWM2OD12LkG4OVU3KM7:TR?=	M{D4[3NCVkeHUh?=
VM-CUB-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfKWYc2UUN3ME20MlMyOjh2IN88US=>	M3fWW3NCVkeHUh?=
CHL-1	M1\Tb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vwSWlEPTB;ND6zNlE3QSEQvF2=	MlX4V2FPT0WU
MDA-MB-361	NVv1WpBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEGxblhKSzVyPUSuN\|MyPTNizszN	M4rlR3NCVkeHUh?=
NCI-H661	NFr2XoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWftfGE5UUN3ME20MlUxODl{IN88US=>	Mo\mV2FPT0WU
EW-11	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmeyTWM2OD12LkWyNlMyKM7:TR?=	MmriV2FPT0WU
BEN	NEGx[llIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PsU2lEPTB;ND61NlgyPSEQvF2=	NHjFbG1USU6JRWK=
BFTC-909	NHSyR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPETWM2OD12LkW2Nlc2KM7:TR?=	M3mzWHNCVkeHUh?=
NCI-H2087	MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jXdGlEPTB;ND61PFE3PCEQvF2=	MWjTRW5ITVJ?
RVH-421	M{DTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG[yUmtKSzVyPUSuOlY3QSEQvF2=	NHvZZZFUSU6JRWK=
P30-OHK	MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHVfYhGUUN3ME20MlY5ODB6IN88US=>	NXL2XllGW0GQR1XS
NCI-H28	MmrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTRwOEG2OlEh\|ryP	MWXTRW5ITVJ?
ES6	MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2ThdmlEPTB;ND64N\|AyPiEQvF2=	M1PpNnNCVkeHUh?=
769-P	NXvVTYpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUO3b4VpUUN3ME20Mlg2QTJ4IN88US=>	M3LTUHNCVkeHUh?=
OE33	M1TWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTRwOEixOlEh\|ryP	MYXTRW5ITVJ?
SW982	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrIVJZKSzVyPUSuPVUxPjFizszN	M{Xx[HNCVkeHUh?=
A388	NWjJfnloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTVwMEK5PFMh\|ryP	NFjNVXJUSU6JRWK=
TI-73	NHHxeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7UfWpKSzVyPUWuNFYyQTRizszN	NYjzfWVDW0GQR1XS
HCT-116	M37iNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWf4d5Z5UUN3ME21MlA6QDh7IN88US=>	NVfhOpRRW0GQR1XS
HuP-T3	NH3QXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDqVm9KSzVyPUWuNVg4ODlizszN	MV\TRW5ITVJ?
G-402	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHGzcZFKSzVyPUWuNVk1OTZizszN	Ml;uV2FPT0WU
NCI-H1792	NYDQdINwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DWR2lEPTB;NT6yOFYzOiEQvF2=	NGm5cpBUSU6JRWK=
NCI-H209	M2X4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTVwMkW5OFIh\|ryP	NXzsTHZDW0GQR1XS
NCI-H1650	NXrESZhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTVwM{C2N\|Qh\|ryP	MXrTRW5ITVJ?
LCLC-97TM1	MnniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUfJR\|UxRTVwM{G4NFgh\|ryP	NYnld5dqW0GQR1XS
S-117	NWTYblZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV35O4wzUUN3ME21MlM3QTd4IN88US=>	M33M[nNCVkeHUh?=
GI-ME-N	MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1XVZWlEPTB;NT6zPVY5OSEQvF2=	MUTTRW5ITVJ?
NCI-H2122	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFP2WIhKSzVyPUWuOFk{QTdizszN	NVXnWWxTW0GQR1XS
NCI-H1793	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGra[WJKSzVyPUWuOlc2QTNizszN	MW\TRW5ITVJ?
C2BBe1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHNTWM2OD13LkewNFg5KM7:TR?=	M2jWOHNCVkeHUh?=
TE-12	NVvlU4NRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDyVpBYUUN3ME21MlgxPTV4IN88US=>	NYSxOm83W0GQR1XS
LCLC-103H	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NILNPZRKSzVyPUWuPVE4KM7:TR?=	NWr2U2ZqW0GQR1XS
A673	Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mme5TWM2OD13LkmxPVMzKM7:TR?=	NX7RN282W0GQR1XS
BB30-HNC	NXiw[WNHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLTTWM2OD13Lkm4N\|Yh\|ryP	MYDTRW5ITVJ?
SF295	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWjBZYtpUUN3ME22MlAxPDJ{IN88US=>	M3y3NXNCVkeHUh?=
KU-19-19	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7pbGJKSzVyPU[uNFE4OzFizszN	NYjvU40yW0GQR1XS
CFPAC-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2Pa[2lEPTB;Nj6wOFQ1OyEQvF2=	NVnkcpZUW0GQR1XS
LoVo	NYPVdJJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFT3boZKSzVyPU[uNFUxPjNizszN	MYTTRW5ITVJ?
8505C	MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTZwMEe1O\|Mh\|ryP	NUL5ZZc2W0GQR1XS
GMS-10	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnPTWM2OD14LkG1NFAzKM7:TR?=	NGnJXmtUSU6JRWK=
Ca9-22	NW[4UpBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFWwWGhKSzVyPU[uNVY4OSEQvF2=	NEXuOZlUSU6JRWK=
DOK	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTZwMkKwO\|Ih\|ryP	MYrTRW5ITVJ?
FADU	NXHx[pl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX:5O4V1UUN3ME22MlI3ODN7IN88US=>	M1rYTHNCVkeHUh?=
BxPC-3	Ml;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HyTGlEPTB;Nj6yO\|MzKM7:TR?=	NE\jXJRUSU6JRWK=
CAL-33	M4rV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWm4Xol1UUN3ME22MlI6OjBzIN88US=>	MULTRW5ITVJ?
SHP-77	M17GZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH34b5dKSzVyPU[uN\|E2OTJizszN	MUPTRW5ITVJ?
LXF-289	NHHzdY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn25TWM2OD14LkOzOFU2KM7:TR?=	MWPTRW5ITVJ?
GB-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzxTWM2OD14LkO4NkDPxE1?	NGfPb3pUSU6JRWK=
KS-1	NIO0coZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGnsTHJKSzVyPU[uN\|g1PDdizszN	MoG4V2FPT0WU
D-502MG	NXGxWnNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmHZTWM2OD14LkSyN\|c3KM7:TR?=	NFjXdHBUSU6JRWK=
LAN-6	NWrFcok2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTZwNUGwNlMh\|ryP	M1fvVnNCVkeHUh?=
H-EMC-SS	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorRTWM2OD14LkW2NVQ4KM7:TR?=	NFL0TpNUSU6JRWK=
LC-2-ad	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTZwNkCwO\|Yh\|ryP	MWnTRW5ITVJ?
NCI-H1693	NFfIWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTMZVhSUUN3ME22MlYzOjF3IN88US=>	M3zC[HNCVkeHUh?=
SK-N-FI	M2PvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmWwTWM2OD14Lke1NFQ1KM7:TR?=	MYTTRW5ITVJ?
D-423MG	NEH5[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37kdGlEPTB;Nj63OlEyPyEQvF2=	NXjxcJZUW0GQR1XS
KNS-42	M1P4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{WwUGlEPTB;Nj63PFE6PyEQvF2=	NX[5S3U1W0GQR1XS
GCT	NYK1OGFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIH6eYxKSzVyPU[uPVM5KM7:TR?=	NUHEbZZ4W0GQR1XS
DSH1	NGWwRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH:yXnJKSzVyPUeuNFY{OyEQvF2=	M1O3bnNCVkeHUh?=
D-247MG	Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7vcoNKSzVyPUeuNFc5QDFizszN	MljOV2FPT0WU
NCI-SNU-5	M1L2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rKW2lEPTB;Nz6xPFM4OSEQvF2=	M3TFc3NCVkeHUh?=
TE-6	NU\keWlMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTdwMkC2NFEh\|ryP	NGTs[YpUSU6JRWK=
NOMO-1	NYT0NZIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TWVWlEPTB;Nz6yNlEzPyEQvF2=	MmrNV2FPT0WU
NB17	M1XXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTdwM{CzNFkh\|ryP	MnvkV2FPT0WU
EW-22	Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETWWXpKSzVyPUeuN\|Q{PDhizszN	NILBfVFUSU6JRWK=
EW-13	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M36wZ2lEPTB;Nz6zOVE3OiEQvF2=	MWnTRW5ITVJ?
DOHH-2	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\mcGlEPTB;Nz60OFAzKM7:TR?=	MnTRV2FPT0WU
TGBC1TKB	NIWyTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTdwNEm4PVkh\|ryP	NInDOmhUSU6JRWK=
GR-ST	M2HQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfRNpRtUUN3ME23MlUzPTl2IN88US=>	MkjNV2FPT0WU
KYSE-520	NInNcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTdwNUW1NVUh\|ryP	MWfTRW5ITVJ?
CAPAN-1	M2nQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rUemlEPTB;Nz61PVUyKM7:TR?=	NEHhTppUSU6JRWK=
HCE-4	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH22c21KSzVyPUeuOlIzPzlizszN	M1XaZnNCVkeHUh?=
MLMA	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jOVmlEPTB;Nz62Nlk2PyEQvF2=	NH7jVpBUSU6JRWK=
HT-144	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LvPGlEPTB;Nz62OVM3QCEQvF2=	Mm\BV2FPT0WU
KYSE-180	M3Pxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\3[\|VDUUN3ME23MlcyOTZ7IN88US=>	MmTIV2FPT0WU
TE-5	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rlXGlEPTB;Nz65OVk4OSEQvF2=	NI\BTppUSU6JRWK=
IGROV-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvpTnR1UUN3ME23Mlk5PTVzIN88US=>	M1KzZnNCVkeHUh?=
NCI-H1581	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPYTWM2OD16LkCxNkDPxE1?	M1PvfnNCVkeHUh?=
SW1990	NET0S\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUP2OlQ5UUN3ME24MlA1PjV7IN88US=>	M1TGUXNCVkeHUh?=
EFM-19	NYWydow{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXGTpBKSzVyPUiuNFg2PDVizszN	NIrnUIFUSU6JRWK=
OGR-1	M2[4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmrITWM2OD16LkSzNFI{KM7:TR?=	NHrENZRUSU6JRWK=
U-118-MG	Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3vRcWlEPTB;OD60N\|Q3OyEQvF2=	MYrTRW5ITVJ?
SK-OV-3	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXUTGtKSzVyPUiuOFY4PjVizszN	NV7vVXhZW0GQR1XS
KNS-62	NEXUN2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRThwNUG3OlEh\|ryP	NXr3dmx6W0GQR1XS
GOTO	MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljNTWM2OD16LkW3OlM2KM7:TR?=	MmfVV2FPT0WU
8305C	NE\zboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHUfW9oUUN3ME24MlcxPDh2IN88US=>	MnmzV2FPT0WU
RPMI-2650	M3nYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2DIWmlEPTB;OD63NVk2PSEQvF2=	M2LFOHNCVkeHUh?=
NEC8	Ml7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRThwN{SzNFch\|ryP	M4jqZ3NCVkeHUh?=
KYSE-450	NWnvdGZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTPNpFKSzVyPUiuPFY2PDhizszN	NUDnNJo3W0GQR1XS
RMG-I	MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTlwMUSwOVgh\|ryP	NHTqUFRUSU6JRWK=
CAKI-1	NX7UfYJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHhdpNGUUN3ME25MlMyQTd7IN88US=>	Mnv3V2FPT0WU
KYSE-510	NV7mTGhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXn5TGRDUUN3ME25MlM2Pzd6IN88US=>	NVWyclBVW0GQR1XS
A4-Fuk	Mm\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nUbmlEPTB;OT6zOlcxOSEQvF2=	MUfTRW5ITVJ?
AN3-CA	NWXLbJFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPNeFdKSzVyPUmuOFU1PDRizszN	M{K0R3NCVkeHUh?=
SK-N-DZ	NGexOVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVy0OmVVUUN3ME25MlczQDR7IN88US=>	NITCe4VUSU6JRWK=
HSC-2	NVrQUYcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mly0TWM2OD17Lke2OlI6KM7:TR?=	M3;tXHNCVkeHUh?=
EW-1	Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzEcml7UUN3ME25Mlc6OzZ7IN88US=>	Moq3V2FPT0WU
D-566MG	NUHhbGU3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XJbWlEPTB;OT64N\|Y3PCEQvF2=	NGfUO4tUSU6JRWK=
COLO-792	NULre3Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;TdW5EUUN3ME25Mlk5PzR4IN88US=>	NFvBeopUSU6JRWK=
TE-10	NYe4XY9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofKTWM2OD1zMD6wN\|k3KM7:TR?=	M4fnd3NCVkeHUh?=
NCI-H650	NGXKXoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPtTWM2OD1zMD60Nlg3KM7:TR?=	NYfqbnE4W0GQR1XS
U-266	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;nT3lKSzVyPUGwMlQ2PSEQvF2=	M4[xeXNCVkeHUh?=
Detroit562	Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHYbYtYUUN3ME2xNU4xPTF3IN88US=>	NFjTXVJUSU6JRWK=
NH-12	NYTWcodTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTFzLkG0OFYh\|ryP	NV7vfotzW0GQR1XS
CO-314	NUXm[nF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7Db5F6UUN3ME2xNU4zQDR{IN88US=>	NVPiR49FW0GQR1XS
IST-MEL1	M1HkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTFzLkWzNlMh\|ryP	NF;GWmpUSU6JRWK=
KNS-81-FD	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\XU4RKSzVyPUGxMlU2OjdizszN	M12yS3NCVkeHUh?=
SW1463	M4HyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGCwN4dKSzVyPUGxMlU6QDlizszN	NFv3dpdUSU6JRWK=
NCI-H23	MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfQd2JKSzVyPUGxMlY2PTJizszN	MlrPV2FPT0WU
SK-MEL-2	NXn4ZoVZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmPETWM2OD1zMT63NVk4KM7:TR?=	NF7XPYxUSU6JRWK=
NB13	M3LjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37IfGlEPTB;MUKuNVQ6PSEQvF2=	NGXXdItUSU6JRWK=
Daoy	NV74NJpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIj5fZBKSzVyPUGyMlI5PTZizszN	NEPaSZpUSU6JRWK=
NCI-H1623	NWW2PHI4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTF{LkO4NFEh\|ryP	NY\oUWQ6W0GQR1XS
NMC-G1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTF{LkexO{DPxE1?	NEm4c3NUSU6JRWK=
DK-MG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7xRZZKSzVyPUGyMlk1QDJizszN	NI\pTJZUSU6JRWK=
TCCSUP	NGPLdJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTF\|LkGyPFQh\|ryP	MW\TRW5ITVJ?
SCC-15	Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NETJbHFKSzVyPUGzMlI3PTFizszN	MnjUV2FPT0WU
NOS-1	NHTqRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWW0XXlOUUN3ME2xN{4zQDl\|IN88US=>	M4O5UnNCVkeHUh?=
RH-1	M4TYRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTF\|LkOwN\|ch\|ryP	NGLPTJFUSU6JRWK=
SK-MEL-3	NH[2fWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnz3TWM2OD1zMz6zO\|I5KM7:TR?=	MX\TRW5ITVJ?
NB5	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPHbIpJUUN3ME2xN{41ODZ5IN88US=>	NF7lPXlUSU6JRWK=
SNU-387	NVzFUY9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTF\|LkWwO\|Ih\|ryP	M1ruc3NCVkeHUh?=
CAL-120	M2rjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vXOGlEPTB;MUOuOlcyQCEQvF2=	MX\TRW5ITVJ?
Mo-T	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\XdWlEPTB;MUOuO\|A4KM7:TR?=	MWnTRW5ITVJ?
LNCaP-Clone-FGC	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHZTWM2OD1zMz63PVkzKM7:TR?=	MkT5V2FPT0WU
CAN	NWHJUnZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XDfmlEPTB;MUSuNFI5QCEQvF2=	MnfDV2FPT0WU
SK-MEL-30	NFrwfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37QS2lEPTB;MUSuNFY{KM7:TR?=	NUTFUo9YW0GQR1XS
COLO-678	MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTuOpB1UUN3ME2xOE4xQDJ{IN88US=>	MnrWV2FPT0WU
SCC-9	Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\x[WlEPTB;MUSuNVAzOSEQvF2=	MmTUV2FPT0WU
KINGS-1	NUXTTY5oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTF2LkG0NFIh\|ryP	M33TNXNCVkeHUh?=
SL-513	M17xTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33rWmlEPTB;MUSuNVg4KM7:TR?=	M{XiNnNCVkeHUh?=
HLE	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXyTWM2OD1zND6zPFUzKM7:TR?=	NH3x[IpUSU6JRWK=
SW1573	M3H6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjXeHlKSzVyPUG0MlQ1OzVizszN	NU\UVFlEW0GQR1XS
KYSE-140	NHXFZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTlTWM2OD1zND62N\|I4KM7:TR?=	MYfTRW5ITVJ?
SK-PN-DW	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\lZmlEPTB;MUSuPFAxOSEQvF2=	MU\TRW5ITVJ?
A253	NXTyWGk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnzOTWM2OD1zNT6wOlI2KM7:TR?=	MW\TRW5ITVJ?
CAL-12T	MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVG3bJF6UUN3ME2xOU41PjZ{IN88US=>	MVPTRW5ITVJ?
COLO-679	M2O3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTF3Lke2PFMh\|ryP	MWTTRW5ITVJ?
UACC-257	MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTF4LkGyNFEh\|ryP	MVXTRW5ITVJ?
U-87-MG	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTF4LkO1NlMh\|ryP	MVHTRW5ITVJ?
HCC1806	MnXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzIdW9KSzVyPUG2MlcxPzFizszN	MV3TRW5ITVJ?
NCI-H2170	MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonMTWM2OD1zNz6yOFQ5KM7:TR?=	MYfTRW5ITVJ?
AGS	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnBRmc{UUN3ME2xO{4{QDB6IN88US=>	M4PXUnNCVkeHUh?=
MEL-HO	NGDvZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mke3TWM2OD1zNz63OVA{KM7:TR?=	NX\0cohTW0GQR1XS
SW48	NXjuRZZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2f3d2lEPTB;MUeuO\|cyPiEQvF2=	MX7TRW5ITVJ?
HuP-T4	NWrIR5I{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHH4SpZKSzVyPUG4MlAzODZizszN	MUjTRW5ITVJ?
NCI-H720	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofxTWM2OD1zOD6xOFAzKM7:TR?=	NGjNWGxUSU6JRWK=
RCC10RGB	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTF6LkG2PVch\|ryP	NGDDbHZUSU6JRWK=
HD-MY-Z	NGrX[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7JR\|UxRTF6LkKyOVQh\|ryP	NUTmVlA1W0GQR1XS
A427	M4HYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4D5e2lEPTB;MUiuOVA6PCEQvF2=	MlftV2FPT0WU
HCC2998	MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoSzTWM2OD1zOD62NFUyKM7:TR?=	MVXTRW5ITVJ?
EPLC-272H	NFLyO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnZ[2VKSzVyPUG5MlA1OzRizszN	MoHTV2FPT0WU
C32	M4D6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTF7LkC0OUDPxE1?	MnrzV2FPT0WU
UMC-11	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTF7LkKxNlMh\|ryP	M3zMdHNCVkeHUh?=
CaR-1	M{XScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPyZmhKSzVyPUG5MlY5ODRizszN	MnPoV2FPT0WU
KYSE-410	NXfodVdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHUSJhKSzVyPUG5MlkyOzlizszN	M3rY[3NCVkeHUh?=
HuCCT1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHz3eYhKSzVyPUKwMlYzQTRizszN	MVvTRW5ITVJ?
LB996-RCC	NGSzRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2j4eWlEPTB;MkCuO\|E3QCEQvF2=	NXnVWlBlW0GQR1XS
KYSE-70	NW\GdWRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPjU2JKSzVyPUKwMlgxPTlizszN	MYrTRW5ITVJ?
CAL-72	NXKyfpVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLsXIh1UUN3ME2yNE46OTVizszN	NUGxfZlsW0GQR1XS
Capan-2	MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHnGZoNKSzVyPUKxMlA1OTNizszN	M4WyZnNCVkeHUh?=
PANC-08-13	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTKdFZWUUN3ME2yNU4zPTF3IN88US=>	MVXTRW5ITVJ?
SBC-1	M4\mOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH:3ZYZKSzVyPUKxMlMxQDFizszN	MV7TRW5ITVJ?
MFM-223	MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkXXTWM2OD1{MT6zN\|QzKM7:TR?=	M4P4TnNCVkeHUh?=
BB49-HNC	M2j6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTuSJNKSzVyPUKxMlU4OTZizszN	M2XFe3NCVkeHUh?=
SH-4	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HtNWlEPTB;MkGuOlYyQCEQvF2=	NFH6bIpUSU6JRWK=
HuO9	Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTJzLkm4NlUh\|ryP	MlnmV2FPT0WU
AM-38	M13tRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTJ{LkC0PFUh\|ryP	MonOV2FPT0WU
A431	MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHWS2RKSzVyPUKzMlIyOTlizszN	MVzTRW5ITVJ?
YAPC	NYTvOoxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;rTWM2OD1{Mz6yOlUyKM7:TR?=	MkTWV2FPT0WU
LU-139	NFLZZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLDXJAxUUN3ME2yN{41QDB7IN88US=>	NFTJ[4xUSU6JRWK=
HEC-1	NFvOUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3;WOGlEPTB;MkOuOFk{PyEQvF2=	MV7TRW5ITVJ?
SCC-25	NVnxdmcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDReIJKSzVyPUK0MlMxODZizszN	MkC3V2FPT0WU
HT-29	M3TDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTJ2LkO4NlMh\|ryP	NWrxb5hZW0GQR1XS
PC-14	M{[wOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTJ2Lk[1O\|Eh\|ryP	MUjTRW5ITVJ?
Calu-6	MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIruNm1KSzVyPUK1MlUxPzFizszN	MV3TRW5ITVJ?
SJRH30	NVHXdXRHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkn0TWM2OD1{NT62OFk3KM7:TR?=	MV;TRW5ITVJ?
ChaGo-K-1	NIrTRVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4jUdGlEPTB;Mk[uNVYzQSEQvF2=	MnHJV2FPT0WU
IA-LM	NFiyeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTJ4LkO2OFUh\|ryP	MnfTV2FPT0WU
GP5d	NILHWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTKfpFKSzVyPUK2MlQ1QTFizszN	M4XI[HNCVkeHUh?=
NCI-H2291	M{C3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2q3TWlEPTB;Mk[uOlU1OSEQvF2=	M{TrUXNCVkeHUh?=
BALL-1	MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PCVGlEPTB;Mk[uPVM6PyEQvF2=	M1PI[nNCVkeHUh?=
HCC1954	NWXB[Hg5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4DTc2lEPTB;Mk[uPVgxQCEQvF2=	MmLsV2FPT0WU
NCI-H2452	NGHmdJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfRbmxDUUN3ME2yO{41OTZ\|IN88US=>	MV\TRW5ITVJ?
LU-99A	NEjEfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{Dv[WlEPTB;MkeuOVU5OiEQvF2=	NGPWSZVUSU6JRWK=
NTERA-S-cl-D1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJ5LkeyPVkh\|ryP	NYDxVZRCW0GQR1XS
PANC-10-05	MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTJ5Lke3O\|Uh\|ryP	M1\GT3NCVkeHUh?=
NCI-H2405	NXH6OlJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTJ5LkmzPFch\|ryP	NIqzWWJUSU6JRWK=
MDA-MB-415	M4\QeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTJ6LkSxN\|ch\|ryP	MV7TRW5ITVJ?
NCI-H2342	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PrVGlEPTB;MkiuOVI5OSEQvF2=	MWTTRW5ITVJ?
TGBC24TKB	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7JZodKSzVyPUK4MlcyOTdizszN	M2LoOHNCVkeHUh?=
LU-134-A	M4rGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTJ6LkmyOlEh\|ryP	MWLTRW5ITVJ?
SCC-4	MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rYVGlEPTB;M{GuNFQ6PCEQvF2=	NVLocZNpW0GQR1XS
Saos-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLncZpSUUN3ME2zNU46OzB4IN88US=>	NGLsTGpUSU6JRWK=
RERF-LC-MS	NXi5[2hIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTN{LkiyN\|Eh\|ryP	M{C3ZXNCVkeHUh?=
M14	MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvBTWM2OD1\|Mj65O\|Y1KM7:TR?=	NHzjWYNUSU6JRWK=
HPAF-II	NWTSZmJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVv1OHFNUUN3ME2zN{42ODFzIN88US=>	MkfGV2FPT0WU
NCI-H1755	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLYTWM2OD1\|ND6zN\|A2KM7:TR?=	MXHTRW5ITVJ?
D-392MG	NU\MTJhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTN3Lki2O\|Qh\|ryP	M2fPSnNCVkeHUh?=
A704	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPJZXZ7UUN3ME2zOk4xPDJ5IN88US=>	M3X1enNCVkeHUh?=
CP50-MEL-B	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;vTWM2OD1\|Nj6xPVEyKM7:TR?=	M3PFOXNCVkeHUh?=
EW-18	NY[wVXpLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;qTWM2OD1\|Nj60OVIh\|ryP	NH\2UoJUSU6JRWK=
WM-115	MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXFS3lrUUN3ME2zOk45ODl7IN88US=>	NFXsPGtUSU6JRWK=
LU-65	MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTN5LkG0NVch\|ryP	NW\MemtlW0GQR1XS
NCI-H1563	NYrmfVl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPwN2NKSzVyPUO3MlI1QDRizszN	Mk\PV2FPT0WU
DBTRG-05MG	M3X1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3npTmlEPTB;M{iuNFY6OSEQvF2=	NHizeFdUSU6JRWK=
NCI-H630	NEHU[npIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3aV5dMUUN3ME2zPE41PzF2IN88US=>	MnHqV2FPT0WU
NCI-H1155	MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFO0UJVKSzVyPUO5MlI1OiEQvF2=	MUDTRW5ITVJ?
OVACR-3	NIXNb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPUOIpKSzVyPUO5MlkyQTVizszN	NVvKRWY3W0GQR1XS
OAW-42	M{jZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rCTGlEPTB;NECuOFI2QCEQvF2=	NHfSR41USU6JRWK=
JVM-2	MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTRzLkK0NVUh\|ryP	MWXTRW5ITVJ?
C3A	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PndWlEPTB;NEGuN\|Q1PyEQvF2=	MVzTRW5ITVJ?
HT55	M2i0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXHZTYNPUUN3ME20Nk4zQDRzIN88US=>	NFnSZYJUSU6JRWK=
OVCAR-4	MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPFWXNKSzVyPUSyMlI6PzRizszN	MXzTRW5ITVJ?
MEG-01	MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTR{LkS2NVYh\|ryP	NIToTlJUSU6JRWK=
NCI-H82	M3;BcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjVemtKSzVyPUSzMlk5QTJizszN	MlLjV2FPT0WU
JEG-3	MoLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;PW\|JrUUN3ME20OE46PDdizszN	M1vwVnNCVkeHUh?=
BPH-1	NHLFeWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLSTWM2OD12Nj6zPVk5KM7:TR?=	Moi1V2FPT0WU
MPP-89	NIXNdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTR5LkK4PVgh\|ryP	MVzTRW5ITVJ?
ALL-PO	M{LIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILuXFRKSzVyPUS3MlQyQDhizszN	M1jaXHNCVkeHUh?=
HT	NU\ESGt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPV[lRqUUN3ME20O{41QTJizszN	MlT6V2FPT0WU
NCI-H2347	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\INGlEPTB;NEiuNFcyPSEQvF2=	NE\6TI1USU6JRWK=
A2780	M{m3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3K3[2lEPTB;NEmuOFIzQCEQvF2=	NILJSXVUSU6JRWK=
KARPAS-299	MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXL3XJlTUUN3ME20PU42OTF7IN88US=>	MmjpV2FPT0WU
NCI-H1651	NFfYTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTR7Lki4NlEh\|ryP	MYDTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; PubMed: 30300583 Cancer Cell Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells. pRb(S807, 811) / CDK4 / CDK6 / PARP; PubMed: 28453226 Mol Oncol Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. LC3-I / LC3-II; PubMed: 28453226 Mol Oncol Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. pAMPKα(T172) / pULK1(S317); PubMed: 28453226 Mol Oncol Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. SMAD2 (pS255); PubMed: 30343527 Cancer Sci T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.	30300583 28453226 30343527
Growth inhibition assay	Cell viability; PubMed: 29670090 Cell Death Dis Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.	29670090
Immunofluorescence	SAHF/ATRX; PubMed: 26988987 Cancer Res DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. LC3B; PubMed: 28453226 Mol Oncol LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).	26988987 28453226
ELISA	PGE2; PubMed: 26540629 Oncotarget The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.	26540629

In vivo

PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse Cdk Assays: A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl₂, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-³²P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-³²P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-³²P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4 °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research: ^[1]	- Collapse Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562 Concentrations: 0.01-1 μM Incubation Time: 24 hours Method: Cells are seeded at 2 × 10⁴ per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [¹⁴C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice. Dosages: 0-150 mg/kg Administration: Given by gavage (Only for Reference)

References

[4] Katsumi Y, et al. Biochem Biophys Res Commun, 2011, 413(1), 62-68.

- Collapse

Solubility (25°C)

In vitro	Water	30 mg/mL (61.98 mM)
	DMSO	3 mg/mL warmed (6.19 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Molecular Weight	483.99
Formula	C₂₄H₂₉N₇O₂.HCl
CAS No.	827022-32-2
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04483505	Not yet recruiting	Drug: Combination Rogaratinib + palbociclib + fulvestrant	Breast Cancer Metastatic\|Hormone Receptor Positive Malignant Neoplasm of Breast	Fundacion CRIS de Investigación para Vencer el Cáncer\|Bayer\|Pfizer\|Apices Soluciones S.L.	October 1 2020	Phase 1
NCT04360941	Recruiting	Drug: Palbociclib\|Drug: Avelumab	Triple Negative Breast Cancer\|Locally Advanced Breast Cancer\|Recurrent Breast Cancer\|Metastatic Breast Cancer\|ER+ Breast Cancer\|HER2-positive Breast Cancer	Royal Marsden NHS Foundation Trust\|Pfizer\|Breast Cancer Now	August 11 2020	Phase 1
NCT03870919	Suspended	Drug: Palbociclib\|Other: locoregional treatment	Breast Cancer Stage IV\|Radiotherapy\|Surgery	UNICANCER\|Pfizer	October 23 2019	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Most Potent CDK Inhibitor

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
CDK Inhibitor in Clinical Trial

Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).
Newest CDK Inhibitor

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. Purvalanol A induces endoplasmic reticulum stress-mediated apoptosis and autophagy.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965, PS-095760) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.
Flavopiridol HCl

Flavopiridol HCl (NSC 649890 HCl, alvocidib, L86-8275, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.
Roscovitine (Seliciclib)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
abemaciclib mesylate (LY2835219)

abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.
SNS-032 (BMS-387032)

SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. SNS-032 (BMS-387032) induces apoptosis. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl